



RECEIVED

JAN 25 1999

WID

GP 1646/boxseq

MAIN CUSTOMER
SERVICE CENTER

PATENT

ATTORNEY DOCKET NO. 07004/002004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jong Lee
Serial No.: 09/016,159
Filed : January 30, 1998
Title : PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN
FRAGMENT AND ANTIBODIES DERIVED THEREFROM

Art Unit: 1646
Examiner: D. Fitzgerald

Assistant Commissioner for Patents
Washington, DC 20231

TRANSMITTAL LETTER

Correspondence relating to this application is enclosed as follows.

1. RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE (1pg)
2. COPY OF NOTICE TO COMPLY (1pg)
2. STATEMENT UNDER 37 CFR §1.821(f) (1pg)
3. STATEMENT UNDER 37 CFR §1.821(f) (1pg)
4. PRELIMINARY AMENDMENT (1pg)
5. PAPER COPY OF SEQUENCE LISTING (7pgs)
6. DISK

Please apply any charges not covered, or any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: January 11, 1999

Mark S. Ellinger
Mark S. Ellinger, Ph.D.
Reg. No. 34,812

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Telephone: 612/335-5070
Facsimile: 612/288-9696
19799.M11

Date of Deposit JANUARY 11, 1999
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Melissa Bergman
Melissa Bergman



PATENT
ATTORNEY DOCKET NO. 07004/002004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jong Lee Art Unit: 1646
Serial No.: 09/016,159 Examiner: D. Fitzgerald
Filed : January 30, 1998
Title : PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN
FRAGMENT AND ANTIBODIES DERIVED THEREFROM

Assistant Commissioner for Patents
Washington, DC 20231


RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

In response to the communication dated December 9, 1998, applicant submits herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicant submits a Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(b).

I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.

Respectfully submitted,


Date: January 11, 1999



Mark S. Ellinger, Ph.D.
Reg. No. 34,812

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Telephone: 612/335-5070
Facsimile: 612/288-9696
19799.M11

Date of Deposit January 11, 1999
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Melissa Dingmann



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§ 1.821-1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a **separate part of the disclosure** on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. § 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. § 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. § 1.821(e).
- ☒ 7. Other:

A paper copy sequence listing was filed with the application. However, no computer-readable copy or request that the Office prepare such copy from the listing filed in the parent application (37 C.F.R. § 1.821(e)) was received. Additionally, no amendment directing entry of the sequence listing into the specification was submitted.

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ ~~An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry of the sequence listing into the specification.~~
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or § 1.821(f) or § 1.821(g) or § 1.825(b) or § 1.825(d).

For questions regarding compliance with these requirements, please contact one of the following:

For rules interpretation, call (703) 308-4216.
For CRF submission help, call (703) 308-4212.
For PatentIn software help, call (703) 557-0400.

Please return a copy of this notice with your response.